Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Results Conference Call February 22, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Patrick Trucchio - H.C. Wainwright Eric Joseph - JP Morgan Alec Stranahan - Bank of America Joseph Stringer - Needha ...

Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results – Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants had HDV RNA less than the lower limit of quantification – – Phase 2 SOLSTICE trial on track to complete enrollment ahead of schedule with initial data expected in the second quarter; greater than 90% of participants d ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________to Commission File Number: ...

Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Patrick Trucchio - H. C. Wainwright Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Joseph Stringer - Needham & Compan ...

© 2023 Vir Biotechnology, Inc. 1 NIR C O R P O R A T E O V E R V I E W Aug 2023 LEGAL DISCLAIMER Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the "Company" or "Vir"), the Company's strategy and plans; financial and operating results and its expectations related thereto; potent ...

FORM 10-Q __________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________ For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________to Commission File Number: 001- ...

Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - EVP and Chief Corporate Affairs Officer Marianne De Backer - CEO Phil Pang - CMO Sung Lee - CFO Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Roanna Ruiz - Leerink Partners Eric Joseph - JPMorgan Eva Privitera - TD Cowen Mike Ulz - Morgan Stanley Joseph Stringer - Needham & Company Patrick Trucchio - H.C. Wainwright Operator Hello. Welcome t ...

© 2023 Vir Biotechnology, Inc. 1 Corporate Overview May 4, 2023 NIR LEGAL DISCLAIMER Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the "Company" or "Vir"), the Company's strategy and plans; capital allocation; future financial and operating results and its expectations related ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 81-2730369 | | --- | --- | | (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact Name of Registrant as Specified in its Charter) Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology, Inc. Delaware 81-2730369 (State or Other Jurisdiction o ...